Micelle‐Based Brain‐Targeted Drug Delivery Enabled by a Nicotine Acetylcholine Receptor Ligand

Abstract

Candid candoxin: A 16-residue peptide (CDX) that is derived from candoxin binds with a high affinity to nicotinic acetylcholine receptors (see picture), which are highly expressed on the blood–brain barrier. In vivo biodistribution and the anti-glioblastoma effect indicate the potential of CDX as a ligand to enable brain-targeted drug delivery.